Essential Partners
HUMA icon

Essential Partners’s Humacyte HUMA Stock Holding History

Essential Partners’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-252
Closed -$197 – 2919
2026
Q2 		$197 Sell
252
-15,756
-98% -$14.6K ﹤0.01% 2638
2026
Q1 		$9.7K Buy
+16,008
New +$16.6K ﹤0.01% 1269
2025
Q4 		– Sell
-267
Closed -$465 – 2836
2025
Q3 		$465 Sell
267
-714
-73% -$1.4K ﹤0.01% 2223
2025
Q2 		$2.05K Buy
+981
New +$1.88K ﹤0.01% 1314

Other funds holding HUMA

Wealth Effects
Wealth Effects Boston, Massachusetts $370M AUM 63.53% 1-Year Est. Return
Miramontes Capital
Miramontes Capital Newport, California $331M AUM 19.33% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Clarus Wealth Advisors
Clarus Wealth Advisors Peoria, Arizona $275M AUM 18.32% 1-Year Est. Return
Lazari Capital Management
Lazari Capital Management Woodland Hills, California $339M AUM 25.58% 1-Year Est. Return
Columbia Advisory Partners
Columbia Advisory Partners Spokane, Washington $181M AUM 18.7% 1-Year Est. Return
Hamilton Lane Advisors
Hamilton Lane Advisors Conshohocken, Pennsylvania $179M AUM 25.1% 1-Year Est. Return
Trilogy Capital
Trilogy Capital Irvine, California $2.61B AUM 14.55% 1-Year Est. Return
Onyx Bridge Wealth Group
Onyx Bridge Wealth Group Tarrytown, New York $1.14B AUM 18.43% 1-Year Est. Return
Valeo Financial Advisors
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.14% 1-Year Est. Return

Essential Partners's HUMA Position: Q3 2026 in Review

Essential Partners sold out of Humacyte (HUMA) in Q3 2026, closing a stake of 252 shares — an estimated $197 sold.

Essential Partners first reported a position in HUMA in Q2 2025 and held it in 4 quarters. The position peaked at $9.7K in Q1 2026. 24 funds tracked by Wall St. Rank hold HUMA as of Q3 2026.

  • Essential Partners reported no remaining Humacyte position as of Q3 2026 after selling out during the quarter.
  • Essential Partners sold 252 Humacyte shares in Q3 2026, an estimated $197.
  • Essential Partners first reported a position in Humacyte in Q2 2025 and held it in 4 quarters.
  • Essential Partners's Humacyte position peaked at $9.7K in Q1 2026.
  • 24 funds tracked by Wall St. Rank held Humacyte as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.